Suppression of pyruvate dehydrogenase kinase-2 re-sensitizes paclitaxel-resistant human lung cancer cells to paclitaxel

Despite impressive initial clinical responses, the majority of lung cancer patients treated with paclitaxel eventually develop resistance to the drug. Pyruvate dehydrogenase kinase-2 (PDK2) is a key regulator of glycolysis and oxidative phosphorylation, and its expression is increased in a variety o...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Hong, Zhu, Anyou, Zhou, Xiang, Wang, Fengchao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5581057/
https://www.ncbi.nlm.nih.gov/pubmed/28881758
http://dx.doi.org/10.18632/oncotarget.16991

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5581057/
https://www.ncbi.nlm.nih.gov/pubmed/28881758
http://dx.doi.org/10.18632/oncotarget.16991

Ejemplares similares